Rituximab plus chemotherapy in follicular and mantle cell lymphomas
- 28 February 2003
- journal article
- clinical trial
- Published by Elsevier BV in Seminars in Oncology
- Vol. 30 (1), 16-20
- https://doi.org/10.1053/sonc.2003.50024
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trialSeminars in Oncology, 2002
- Rituximab: Mechanism of action and resistanceSeminars in Oncology, 2002
- Rituximab: mechanisms and applicationsBritish Journal of Cancer, 2001
- Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in JapanCancer Chemotherapy and Pharmacology, 2001
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood, 2001
- Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-TreatmentJournal of Clinical Oncology, 2000
- IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study GroupAnnals of Hematology, 2000
- Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of RituximabJournal of Clinical Oncology, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic DrugsCancer Biotherapy & Radiopharmaceuticals, 1997